摘要
为评价华法林用于持续性心房颤动 (简称房颤 )患者抗凝治疗的安全性 ,对 5 4 0例持续性房颤患者进行华法林抗凝治疗 ,观察治疗过程中的出血及其它不良反应。结果 :华法林用量为 2 .5 4± 0 .7(1～ 6 )mg/d ,治疗维持国际标准化率 (INR)在 2～ 3范围时 ,轻度出血率为 3.15 % ,经相关处理并调低INR值 ,所有出血均停止 ;无一例因严重出血而终止抗凝治疗 ;未见其它不良反应。 75岁以上房颤者出血发生率增加。结论 :持续性房颤患者应用华法林抗凝治疗时 ,INR维持在 2～ 3范围可能是安全的 ;轻度出血患者经调低INR值 ,出血可以停止 ,不影响继续抗凝治疗。
To assess the safety of warfarin in the treatment of anticoagulation in the patients with persistent atrial fibrillation,the hemorrhage and other adverse effect of warfarin therapy were observed in 540 patients with persistent atrial fibrillation.Results:The dose of warfarin was 2.54±0.7(1～6) mg/d and the INR ranged from 2 to 3,the rate of slight hemorrhage was 3.15%. No one terminated the treatment due to severe hemorrhage.The rate of hemorrhage increased in the patients with over 75 years old. Conclusions: It is safe for the patients with persistent atrial fibrillation using warfarin while the INR ranges from 2 to 3;INR should be monitored when warfarin is used to anticoagulate in the patients with persistent atrial fibrillation.
出处
《中国心脏起搏与心电生理杂志》
2004年第6期435-437,共3页
Chinese Journal of Cardiac Pacing and Electrophysiology
关键词
心血管病学
心房颤动
抗凝
华法林
Cardiology Atrial,fibrillation Anticoagulation,Warfarin
